Bartlett & Co. LLC boosted its position in Gilead Sciences Inc. (NASDAQ:GILD) by 1.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 334,952 shares of the biopharmaceutical company’s stock after buying an additional 4,881 shares during the period. Gilead Sciences makes up 1.4% of Bartlett & Co. LLC’s portfolio, making the stock its 26th largest position. Bartlett & Co. LLC’s holdings in Gilead Sciences were worth $27,942,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Joel Isaacson & Co. LLC raised its position in shares of Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 226 shares during the last quarter. Jolley Asset Management LLC raised its position in shares of Gilead Sciences by 67.3% in the second quarter. Jolley Asset Management LLC now owns 1,696 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 682 shares during the last quarter. Loomis Sayles & Co. L P raised its position in shares of Gilead Sciences by 23.3% in the first quarter. Loomis Sayles & Co. L P now owns 1,591 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 301 shares during the last quarter. North Star Investment Management Corp. raised its position in shares of Gilead Sciences by 47.8% in the second quarter. North Star Investment Management Corp. now owns 2,165 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 700 shares during the last quarter. Finally, Peoples Financial Services CORP. raised its position in shares of Gilead Sciences by 30.4% in the second quarter. Peoples Financial Services CORP. now owns 2,575 shares of the biopharmaceutical company’s stock worth $215,000 after buying an additional 600 shares during the last quarter. 77.93% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 2.21% during trading on Tuesday, reaching $73.82. 11,892,516 shares of the company’s stock traded hands. The company has a 50 day moving average price of $78.79 and a 200-day moving average price of $84.83. Gilead Sciences Inc. has a one year low of $73.56 and a one year high of $111.11. The stock has a market cap of $97.42 billion, a P/E ratio of 6.48 and a beta of 1.10.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.02 by $0.06. The business earned $7.78 billion during the quarter, compared to analyst estimates of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The company’s quarterly revenue was down 5.7% on a year-over-year basis. During the same period in the prior year, the firm posted $3.15 earnings per share. On average, equities research analysts expect that Gilead Sciences Inc. will post $11.76 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were issued a dividend of $0.47 per share. The ex-dividend date was Wednesday, September 14th. This represents a $1.88 annualized dividend and a dividend yield of 2.55%. Gilead Sciences’s dividend payout ratio (DPR) is currently 16.56%.

GILD has been the subject of a number of research reports. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $120.00 price objective on shares of Gilead Sciences in a research note on Wednesday, June 29th. Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $95.02 price objective for the company. in a research note on Wednesday, July 6th. Leerink Swann reaffirmed a “buy” rating and issued a $120.00 price objective on shares of Gilead Sciences in a research note on Tuesday, June 21st. Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $97.00 price objective for the company in a research note on Monday, July 11th. Finally, RBC Capital Markets set a $105.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, August 11th. Ten equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $104.71.

In related news, insider John C. Martin sold 100,000 shares of the stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $80.50, for a total value of $8,050,000.00. Following the transaction, the insider now owns 4,119,727 shares in the company, valued at approximately $331,638,023.50. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $81.84, for a total transaction of $409,200.00. Following the completion of the transaction, the executive vice president now owns 132,964 shares in the company, valued at approximately $10,881,773.76. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.